← Tarsus Pharmaceuticals, Inc. (TARS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Tarsus Pharmaceuticals, Inc. (TARS)
Biological Products, (No Diagnostic Substances) · market cap $3.3B · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-03 (est.)
Earnings
Pipeline
6
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Tarsus Pharmaceuticals (TARS) is a commercial-stage biotech with 323 employees and a ~$2.55B market cap, built around lotilaner-based topical treatments for ocular and dermatological conditions. Its lead approved asset, TP-03, addresses Demodex blepharitis, and the company has expanded the pipeline into Meibomian Gland Dysfunction, papulopustular rosacea, and Lyme disease. Revenue scaled sharply from $17M in 2023 to $451M in 2025, though the company remains unprofitable with $102M cash and roughly 12 months of runway.
The catalyst path
- 2026-11-03 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| TP-03 Vehicle | Phase 3 | Blepharitis |
| TP-03, 0.25% | Phase 3 | Blepharitis |
| Lotilaner Gel, 2.0% | Phase 2 | Papulopustular Rosacea |
| Low Dose TP-05 | Phase 2 | Healthy Volunteer |
| TP-05 (lotilaner) Low Dose | Phase 2 | Lyme Disease |
| TP-03 | Phase 3 | Meibomian Gland Dysfunction |
Price & technical context
3-month
+15.3%
6-month
+7.5%
12-month
+27.0%
52-wk range
$56.11–$90.78
vs 50-day MA
+4.6%
vs 200-day MA
+10.0%
Realized vol
45.7%
Max drawdown
-32.0%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for TARS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.